Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8N1H7
UPID:
S6OS1_HUMAN
Alternative names:
Six6 opposite strand transcript 1
Alternative UPACC:
Q8N1H7; Q08AQ4
Background:
Protein SIX6OS1, also known as Six6 opposite strand transcript 1, plays a pivotal role in meiosis, specifically in chromosome synapsis during meiotic recombination. It localizes to the central element of the synaptonemal complex and is essential for the processing of intermediate recombination nodules before crossover formation.
Therapeutic significance:
SIX6OS1 is implicated in Spermatogenic failure 52 and Premature ovarian failure 18, both of which are reproductive disorders caused by gene variants. Understanding the role of Protein SIX6OS1 could open doors to potential therapeutic strategies for these infertility disorders.